Medicine for prevention of and treatment for arteriosclerosis and hypertension

Details for Australian Patent Application No. 2004208615 (hide)

International Classifications

Event Publications

15 September 2005 PCT application entered the National Phase

PCT publication WO2004/067003 Priority application(s): WO2004/067003

3 May 2007 Application Accepted

Published as AU-B-2004208615

30 August 2007 Standard Patent Sealed

4 October 2007 Assignment Registered

Sankyo Company, Limited The patent has been assigned to Daiichi Sankyo Company, Limited

24 December 2009 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 22 Oct 2009. Address for service in Australia - Davies Collison Cave 1 Nicholson Street Melbourne VIC 3000

13 May 2010 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 22 Oct 2009

26 August 2010 Extension of Term of Standard Patents

Daiichi Sankyo Company, Limited The earliest first regulatory approval date provided by the patentee 14 May 2010 For the goods SEVIKAR olmesartan medoxomil/amlodipine (as besylate) Applications Accepted The following application(s) for Extension of Term have been accepted under Section 74. Notice of opposition under Section 75(1) to the undermentioned application(s) for an extension of term may be filed at the Patent Office within the prescribed time.

2 September 2010 Extension of Term of Standard Patents

27 January 2011 Extension granted

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.